Search
According to a Future Market Insights report, the global medical IoT market is expected to reach US$280.5 billion by 2026, increasing to US$1,164.8 billion by 2036, with a compound annual growth rate of 15.3%. Hardware accounts for 46%, telemedicine for 32%, and India is the fastest-growing market.
The global clinical trial market size is expected to reach $143.46 billion by 2033, with AI and decentralized models reshaping the drug development landscape.
The global medical device market was valued at $537.38 billion in 2025 and is expected to reach $826.53 billion by 2034. The integration of population aging and AI technology is reshaping the industry landscape, with minimally invasive surgery and remote monitoring becoming growth highlights.
The Business Research Company's latest report shows that the global medical device market is expected to achieve a CAGR of 9.2% from 2026 to 2030, with AI, digital health, and smart hospitals becoming the core growth drivers.
The global digital health market is expected to reach $2.19 trillion by 2034, with a compound annual growth rate of 22.5%. The North American market leads, with telehealth and AI as the main drivers.
The global wearable medical device market is expected to reach $167.8 billion by 2035, with a compound annual growth rate of 14.2%. Driven by policy, technology, and capital, the healthcare industry is undergoing a transition from periodic checkups to continuous monitoring.
Medical AI has moved from experimentation to clinical practice, but the practical application of diagnosis, treatment, and decision support still faces challenges in data, trust, and integration. This article reviews the current state and future trends.
The U.S. FDA has announced that Dexcom is the first participant in its TEMPO Digital Health Pilot Program, which allows certain digital health devices to be exempt from premarket review while collecting real-world data through Medicare. Dexcom plans to use AI and continuous glucose monitoring technology to screen for prediabetes and type 2 diabetes, marking a deep integration of regulatory innovation and payment reform.
The U.S. FDA has selected Dexcom as the first participant in the TEMPO digital health device pilot. The AI-driven blood glucose management program will be granted exemption from certain premarket approval requirements, while collecting real-world data through Medicare.
MiniMed launches the Abbott-manufactured Instinct continuous glucose monitor in Europe, targeting over 4.5 million Abbott CGM users, aiming to drive insulin pump sales growth through sensor selection.
At the American Diabetes Association Scientific Sessions, Insulet, MiniMed, Dexcom, and Abbott showcased cutting-edge technologies including fully closed-loop insulin delivery systems, new evidence for continuous glucose monitoring, and multi-analyte sensors.
As GLP-1 drugs evolve from injectables to oral, multi-target, and RNA therapies, the entire metabolic disease treatment market is undergoing profound changes. This article analyzes the latest industry trends, key company strategies, and development directions over the next 3-5 years.